<DOC>
	<DOCNO>NCT01469130</DOCNO>
	<brief_summary>In study , MEK162 administer Japanese patient advance solid tumor whose disease progress despite standard therapy standard therapy exist . The trial investigate safety tolerability determine MTD MEK162 Japanese patient .</brief_summary>
	<brief_title>A Phase I Study Oral MEK162 Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients histologicallyconfirmed , advance unresectable solid tumor progress within three month screening/baseline visit . Availability representative formalin fix paraffin embed tumor tissue sample . At least one measurable nonmeasurable lesion Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Good organ ( hepatic , kidney , BM ) function screening/baseline visit . Brain metastasis unless treat free signs/symptoms attributable brain metastasis absence corticosteroid therapy antiepileptic therapy . Impaired cardiac function clinically significant cardiac disease incl . unstable angina pectoris ≤ 3 month prior start study drug Acute Myocardial Infarction ( AMI ) ≤ 3 month prior start study drug . Women pregnant breast feeding adult reproductive potential employ effective method birth control . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEK , Advanced solid tumor</keyword>
</DOC>